Preclinical and clinical development considerations for biologics in USA MCQs With Answer

Introduction

Preclinical and clinical development considerations for biologics in the USA is designed for M.Pharm students to build a clear regulatory perspective on developing biological products. This blog focuses on the US regulatory framework—FDA expectations for investigational new drug (IND) and biologics license applications (BLA)—and the nonclinical work needed: GLP toxicology, species selection, immunogenicity assessment, PK/PD, and safety pharmacology. It also covers clinical trial design, dose selection, biosimilar pathways, pediatric and post-marketing requirements, and important concepts such as comparability and analytic similarity. The questions that follow reinforce critical concepts and prepare students for regulatory decision-making in biologic development.

Q1. Which components are typically required in an IND submission for a biologic in the USA?

• Only the clinical protocol and investigator information
• Preclinical safety and pharmacology data, CMC information, and clinical protocols
• Marketing plan and proposed sales projections
• Only manufacturing batch release certificates

Correct Answer: Preclinical safety and pharmacology data, CMC information, and clinical protocols

Q2. Good Laboratory Practice (GLP) regulations in the context of biologic development apply primarily to which of the following?

• Clinical pharmacology studies in humans
• Nonclinical safety studies intended to support regulatory submissions
• Analytical method validation for release testing
• Marketing and promotional material testing

Correct Answer: Nonclinical safety studies intended to support regulatory submissions

Q3. How is the recommended starting dose for first-in-human trials commonly derived for a novel biologic?

• Using the highest dose tolerated in placebo-controlled human studies
• From the animal NOAEL converted to a human equivalent dose using body surface area scaling and applying a safety factor
• Based only on in vitro potency without animal data
• By dividing the intended therapeutic dose by ten arbitrarily

Correct Answer: From the animal NOAEL converted to a human equivalent dose using body surface area scaling and applying a safety factor

Q4. For immunogenicity assessment of biologics, regulatory guidance recommends inclusion of which assay types?

• Only mass spectrometry-based assays
• Binding antibody assays and neutralizing antibody assays
• Only clinical symptom checklists without laboratory assays
• Only cell-based potency assays unrelated to ADA detection

Correct Answer: Binding antibody assays and neutralizing antibody assays

Q5. When selecting animal species for toxicology studies of a biologic, the most important criterion is:

• Availability of animals in the laboratory vendor
• Pharmacologic relevance demonstrated by target binding and similar pharmacodynamics
• Species similarity in coat color
• Only the historical use of that species in small molecule testing

Correct Answer: Pharmacologic relevance demonstrated by target binding and similar pharmacodynamics

Q6. Toxicokinetic data in nonclinical studies are important because they:

• Are optional and rarely used for biologic submissions
• Help interpret safety margins by relating exposure to observed toxicities
• Only provide information on drug manufacturing yield
• Replace the need for any clinical pharmacokinetic studies

Correct Answer: Help interpret safety margins by relating exposure to observed toxicities

Q7. According to ICH S6(R1), carcinogenicity studies for monoclonal antibodies are:

• Always mandatory prior to any clinical trial
• Generally not required routinely due to species specificity, unless there is a specific concern
• Never considered under any circumstances
• Only required if the product is produced in bacteria

Correct Answer: Generally not required routinely due to species specificity, unless there is a specific concern

Q8. Reproductive and developmental toxicity testing for biologics is typically conducted when:

• The therapeutic target has known roles in reproduction or exposure of reproductive-age patients is expected
• The product is only intended for topical use in elderly patients
• Only when the biologic is derived from bacterial fermentation
• It is never required for any biologic

Correct Answer: The therapeutic target has known roles in reproduction or exposure of reproductive-age patients is expected

Q9. The regulatory pathway in the United States specifically enabling approval of biosimilars is outlined under which section?

• 21 CFR Part 11
• Section 351(k) of the Public Health Service Act
• Food, Drug, and Cosmetic Act Section 505(b)(1)
• Orphan Drug Act

Correct Answer: Section 351(k) of the Public Health Service Act

Q10. Which element is considered the cornerstone of demonstrating biosimilarity to a reference biologic?

• Identical manufacturing site location
• Extensive analytical characterization showing high similarity in structure and function
• Matching the brand name labeling
• Conducting only one small clinical trial without analytical data

Correct Answer: Extensive analytical characterization showing high similarity in structure and function

Q11. To gain US interchangeability designation for a biosimilar, a sponsor must generally provide data showing:

• The biosimilar is less effective than the reference product
• Expected same clinical result in any given patient and no greater risk with alternating or switching
• Only analytical similarity without clinical data
• That the biosimilar has different indications than the reference product

Correct Answer: Expected same clinical result in any given patient and no greater risk with alternating or switching

Q12. In pharmacokinetic equivalence studies for a biosimilar, commonly accepted equivalence margins for AUC and Cmax are:

• 50% to 200%
• 80% to 125%
• Only exact 100% is acceptable
• Margins are not applicable to PK studies

Correct Answer: 80% to 125%

Q13. First-in-human studies for oncology biologics are often initiated in which population?

• Healthy volunteers only
• Patients with advanced or refractory cancer
• Pediatric healthy volunteers
• Only elderly volunteers with no disease

Correct Answer: Patients with advanced or refractory cancer

Q14. A Risk Evaluation and Mitigation Strategy (REMS) for a biologic is implemented primarily to:

• Increase the advertising budget for the product
• Mitigate specific serious safety risks to ensure benefits outweigh risks
• Reduce manufacturing costs
• Allow use of unvalidated analytical methods

Correct Answer: Mitigate specific serious safety risks to ensure benefits outweigh risks

Q15. Under US regulations, the Pediatric Study Plan (PSP) required by FDA addresses:

• The need for pediatric studies and a timeline for their submission under PREA
• Only the marketing strategy for pediatric labeling
• Pediatric vaccine storage conditions
• Exemption from any pediatric data for all biologics

Correct Answer: The need for pediatric studies and a timeline for their submission under PREA

Q16. Accelerated approval for a biologic can be granted when clinical benefit is demonstrated by:

• Any laboratory value irrespective of clinical relevance
• A surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit
• Marketing authorization in another country only
• Only animal efficacy data

Correct Answer: A surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit

Q17. Post-marketing commitments for biologics commonly include:

• Conducting additional clinical studies to verify clinical benefit or to investigate safety signals
• Only aesthetic changes to the product label
• Immediate cessation of monitoring after approval
• Reducing potency specifications to increase yield

Correct Answer: Conducting additional clinical studies to verify clinical benefit or to investigate safety signals

Q18. Comparative immunogenicity assessments between a biosimilar and reference product should include:

• Only historical literature review without patient samples
• Parallel assessment of anti-drug antibody incidence, titers, and neutralizing activity in an appropriate clinical study
• Only in vitro gene expression profiling
• No assessment is needed if analytical similarity is shown

Correct Answer: Parallel assessment of anti-drug antibody incidence, titers, and neutralizing activity in an appropriate clinical study

Q19. A comparability exercise following a manufacturing change for a biologic should primarily demonstrate:

• That the product’s name has changed
• That the post-change product is comparable to the pre-change product with respect to quality, purity, and potency
• Only a change in the marketing label
• That clinical trials are no longer necessary for any future changes

Correct Answer: That the post-change product is comparable to the pre-change product with respect to quality, purity, and potency

Q20. Adaptive clinical trial designs for biologics are characterized by which regulatory expectation?

• Unplanned mid-trial changes without documentation are acceptable
• Pre-specified adaptation rules and control of Type I error with appropriate interim analyses
• They eliminate the need for any statistical planning
• They are prohibited for biologic products

Correct Answer: Pre-specified adaptation rules and control of Type I error with appropriate interim analyses

Download